Skip to main content

Table 1 Characteristics of HIV Subgroups

From: Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study

Characteristic

EI-AED

NEI-AED

Non-AED

EI-AED vs.

NEI-AED

(p-values)

EI-AED vs.

Non-AED

(p-values)

Number, n

19

85

190

  

Demographics (n, % or mean ± SD)

     

   Age at HIV diagnosis (y)

30.2 ± 10.0

32.5 ± 8.9

30.0 ± 7.9

0.331

0.912

   Age at first HAART/AED overlap or index HAART (y)

40.1 ± 8.7

45.1 ± 9.0

38.7 ± 9.1

0.027

0.522

   Female

1 (5.3)

13 (15.3)

18 (9.5)

0.249

0.544

   Race/ethnicity

   

0.323

0.137

European American

13 (68.4)

46 (54.1)

89 (46.8)

  

African American

6 (31.6)

32 (37.6)

84 (44.2)

  

Other

0 (0.0)

7 (8.2)

17 (8.9)

  

   Year of HIV diagnosis (median, range)

1988 (1985 - 2000)

1990 (1986 - 1999)

1990 (1985 - 2000)

0.145

0.122

   CD4+ at HIV diagnosis (cells/uL)

632 ± 398

525 ± 321

483 ± 235

0.340

0.068

   CD4+ at first HAART/AED overlap or index HAART (cells/uL)

310 ± 290

380 ± 247

364 ± 232

0.329

0.392

   Viral load (log10) at first HAART/AED overlap or index HAART (copies/mL)

3.8 ± 1.6

3.1 ± 1.4

3.6 ± 1.4

0.075

0.572

   AIDS-defining event prior to first HAART/AED overlap or index HAART

11 (57.9)

35 (41.2)

40 (21.1)

0.187

<.001

HAART regimen at first HAART/AED overlap or index HAART (n, %)

   

0.189

0.543

   PI-based

12 (63.2)

35 (41.2)

117 (61.6)

  

   NNRTI-based

5 (26.3)

29 (34.1)

36 (18.9)

  

   PI + NNRTI

2 (10.5)

21 (24.7)

37 (19.5)

  

Number of HAART/AED overlap periods (n, %)

   

0.343

---

   1

7 (36.8)

47 (55.3)

---

  

   2

5 (26.3)

17 (20.0)

---

  

   ≥ 3

7 (36.8)

21 (24.7)

---

  

Months of HAART/AED overlap (median, range)

     

   First overlap period

7.0 (1.0 - 96.4)

9.1 (1.3 - 65.4)

---

0.231

---

   All overlap periods

21.3 (1.0 - 155.4)

22.1 (1.6 - 120.3)

---

0.798

---

Year of first HAART/AED overlap or index HAART (median, range)

1998 (1996 - 2006)

2003 (1996 - 2009)

1998 (1996 - 2006)

0.002

1.000

HAART use prior to first HAART/AED overlap or index HAART (n, %)

   

0.010

0.523

   No prior HAART

4 (21.1)

6 (7.1)

40 (21.1)

  

   <1 year

4 (21.1)

7 (8.2)

37 (19.5)

  

   1-2 years

2 (10.5)

7 (8.2)

31 (16.3)

  

   2-3 years

4 (21.1)

6 (7.1)

17 (8.9)

  

   >3 years

5 (26.3)

59 (69.4)

65 (34.2)

  

Duration of first HAART/AED overlap or index HAART (n, %)

   

0.144

0.495

   <1 year

10 (52.6)

22 (25.9)

69 (36.3)

  

   1-2 years

4 (21.1)

22 (25.9)

63 (33.2)

  

   2-3 years

2 (10.5)

15 (17.6)

31 (16.3)

  

   >3 years

3 (15.8)

26 (30.6)

27 (14.2)

  
  1. EI-AED, enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital); NEI-AED, antiepileptics that are not enzyme-inducing; Non-AED, subgroup of all subjects in the cohort (exclusive of other groups) matched according to year of HAART start and number of previous HAART regimens; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor